Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P49767
UPID:
VEGFC_HUMAN
Alternative names:
Flt4 ligand; Vascular endothelial growth factor-related protein
Alternative UPACC:
P49767; B2R9Q8
Background:
Vascular endothelial growth factor C (VEGF-C), also known as Flt4 ligand or VEGF-related protein, plays a pivotal role in angiogenesis and endothelial cell growth. It stimulates proliferation, migration, and influences the permeability of blood vessels. VEGF-C is crucial in the development of the venous and lymphatic vascular systems during embryogenesis and maintains differentiated lymphatic endothelium in adults, activating KDR/VEGFR2 and FLT4/VEGFR3 receptors.
Therapeutic significance:
VEGF-C's involvement in Lymphatic malformation 4, characterized by lymphedema and impaired lymphatic function, underscores its therapeutic potential. Targeting VEGF-C could lead to innovative treatments for lymphatic disorders, offering hope for patients suffering from such conditions.